Kaplan–Meier survival analysis unequivocally demonstrated that high MZT2B expression was significantly correlated with diminished overall survival in NSCLC patients (Fig. 1K, P = 0.002, HR = 1.61, 95% CI: 1.20–2.16). Here, MZT2B is linked to non-small cell lung carcinoma.